title: Foscarnet therapy of cytomegalovirus retinitis in AIDS.
abstract: Cytomegalovirus (CMV) retinitis is the most common cause of blindness in AIDS. Twenty patients were treated with a 21-day course of foscarnet therapy by continuous infusion. Response to therapy was good in eight (47%) of 17 evaluable patients; partial arrest of progression was observed in eight (47%); and no response was obtained in one (6%). Foscarnet therapy did not lead to suppression of urinary excretion of CMV in four of 12 patients who nonetheless had improvement in retinal lesions. Toxic effects, especially reversible renal failure, were common, with blood creatinine increase in 50% and dialysis in two patients. Renal toxicity occurred primarily during the third week of therapy. Anemia (hemoglobin less than 80 g/L) occurred in 10 patients after a mean of 14.5 +/- 5.1 days of therapy and required transfusion. Review of this study and of data from a previous case series, however, was inconclusive regarding the additional benefit of a third week of therapy. Maintenance therapy was given to seven patients. Four had recurrence of CMV retinitis at a mean interval of 62 +/- 52 days. Only one patient has maintained prolonged remission on maintenance (greater than 24 weeks). Toxicity on the maintenance protocol included anemia (two of seven patients) and increased creatinine blood levels (one of seven patients). Zidovudine therapy in six patients did not contribute to increased toxicity of induction or maintenance therapy. Drug levels during continuous infusion were stable for individual patients but showed wide inter-patient variability. Peak levels of post-maintenance infusion varied both within and between patients.
authors.affiliation: Department of Pediatrics, University of Toronto, Ontario, Canada.
authors.forename: M M
authors.initials: MM
authors.lastname: Fanning
authors.forename: S E
authors.initials: SE
authors.lastname: Read
authors.forename: M
authors.initials: M
authors.lastname: Benson
authors.forename: S
authors.initials: S
authors.lastname: Vas
authors.forename: A
authors.initials: A
authors.lastname: Rachlis
authors.forename: V
authors.initials: V
authors.lastname: Kozousek
authors.forename: C
authors.initials: C
authors.lastname: Mortimer
authors.forename: P
authors.initials: P
authors.lastname: Harvey
authors.forename: C
authors.initials: C
authors.lastname: Schwartz
authors.forename: E
authors.initials: E
authors.lastname: Chew
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy*; D017245:Foscarnet; D006801:Humans; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012173:Retinitis / Q000150:complications / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000998:Antiviral Agents; D017245:Foscarnet; D010746:Phosphonoacetic Acid